Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Ablymico

Ablymico 6 mg/mL solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 10

HOS-153845 · Präparat HOS-101056

Hypoglycaemia in patients with type 2 diabetes mellitus treated with insulin In a clinical trial in overweight or obese patients with type 2 diabetes mellitus treated with insulin and liraglutide 3.0 mg/day in combination with diet and exercise and up to 2 OADs, severe hypoglycaemia (requiring third party assistance) was reported by 1.5 % of patients treated with liraglutide 3.0 mg/day. In this trial, documented symptomatic hypoglycaemia (defined as plasma glucose ≤ 3.9 mmol/l accompanied by symptoms) was reported by 47.2 % of patients treated with liraglutide 3.0 mg/day and by 51.8 % of patients treated with placebo. Among patients concomitantly treated with sulfonylurea, 60.9 % of patients treated with liraglutide 3.0 mg/day and 60.0 % of patients treated with placebo reported documented symptomatic hypoglycaemic events.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.